Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
1. A method of initiating systemic aripiprazole treatment in a patient, comprising initially intramuscularly administering to the patient 66% to 75% of a 300 or 400 mg weight equivalent dose of aripiprazole in the form of a long-acting drug-containing suspension which systemically releases aripiprazole, wherein the dose is released over a period of about one month, and wherein the patient is a CYP2D6 and CYP3A4 extensive metabolizer and is concomitantly administered a strong CYP2D6 inhibitor or a strong CYP3A4 inhibitor.
2. The method of claim 1 , wherein 66% to 75% of a 300 mg weight equivalent dose of aripiprazole is administered.
3. The method of claim 1 , wherein 66% of a 300 mg weight equivalent dose of aripiprazole is administered.
4. The method of claim 1 , wherein 66% to 75% of a 400 mg weight equivalent dose of aripiprazole is administered.
5. The method of claim 1 , wherein 75% of a 400 mg weight equivalent dose of aripiprazole is administered.
6. The method of claim 1 , wherein the long-acting drug-containing suspension comprises a prodrug of aripiprazole.
7. The method of claim 1 , wherein the long-acting drug-containing suspension comprises aripiprazole.
8. The method of claim 6 , wherein the long-acting drug-containing suspension comprises (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.
9. A method of initiating systemic aripiprazole treatment in a patient, comprising initially intramuscularly administering to the patient 75% of a 300 or 400 mg weight equivalent dose of aripiprazole in the form of a long-acting drug-containing suspension which systemically releases aripiprazole, wherein the dose is released over a period of about one month, and wherein the patient is a CYP2D6 poor metabolizer not concomitantly administered a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor.
10. The method of claim 9 , wherein 75% of a 300 mg weight equivalent dose of aripiprazole is administered.
11. The method of claim 9 , wherein 75% of a 400 mg weight equivalent dose of aripiprazole is administered.
12. The method of claim 9 , wherein the long-acting drug-containing suspension comprises a prodrug of aripiprazole.
13. The method of claim 9 , wherein the long-acting drug-containing suspension comprises aripiprazole.
14. The method of claim 12 , wherein the long-acting drug-containing suspension comprises (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.
15. A method of initiating systemic aripiprazole treatment in a patient, comprising initially intramuscularly administering to the patient 53% of a 300 mg or 50% of a 400 mg weight equivalent dose of aripiprazole in the form of a long-acting drug-containing suspension which systemically releases aripiprazole, wherein the dose is released over a period of about one month, and wherein the patient is a CYP2D6 and CYP3A4 extensive metabolizer and is concomitantly administered a strong CYP2D6 inhibitor and a strong CYP3A4 inhibitor.
16. The method of claim 15 , wherein 53% of a 300 weight equivalent dose of aripiprazole is administered.
17. The method of claim 15 , wherein 50% of a 400 mg weight equivalent dose of aripiprazole is administered.
18. The method of claim 15 , wherein the long-acting drug-containing suspension comprises a prodrug of aripiprazole.
19. The method of claim 15 , wherein the long-acting drug-containing suspension comprises aripiprazole.
20. The method of claim 18 , wherein the long-acting drug-containing suspension comprises (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.